Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.

Badran AS, Helal A, Shata KS, Ayesh H

Obesity research & clinical practice16 Jan 2026

PMID41545261DOI10.1016/j.orcp.2026.01.002PepBankPUB-41545261

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with HIV-associated lipodystrophy, tesamorelin significantly reduced visceral adipose tissue versus placebo in a meta-analysis of randomized trials.
In plain wordsIn adults with HIV-related fat redistribution, tesamorelin reduced belly (visceral) fat more than placebo.
Peptide
Tesamorelin
Outcome
DecreaseVisceral adipose tissue change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD visceral adipose tissue
−27.71 cm²
tesamorelin versus placebo
Source sentences
Summary
visceral adipose tissue (MD=-27.71 cm², 95 % CI [-38.37, -17.06]; P < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorelin versus placebo in adults with HIV.
Summary · context
Five RCTs evaluating Tesamorelin were included in the analysis.
Report a problemFND-4154526101
02HumanSystematic reviewEfficacy outcome
In adults with HIV-associated lipodystrophy, tesamorelin significantly reduced trunk fat versus placebo.
In plain wordsIn adults with HIV-related fat redistribution, tesamorelin reduced trunk fat more than placebo.
Peptide
Tesamorelin
Outcome
DecreaseTrunk fat change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD trunk fat
−1.18 kg
tesamorelin versus placebo
Source sentences
Summary
trunk fat (MD=-1.18 kg, 95 % CI [-1.40, -0.96]; P < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorelin versus placebo in adults with HIV.
Summary · context
Five RCTs evaluating Tesamorelin were included in the analysis.
Report a problemFND-4154526102
03HumanSystematic reviewEfficacy outcome
In adults with HIV-associated lipodystrophy, tesamorelin significantly reduced limb fat versus placebo.
In plain wordsIn adults with HIV-related fat redistribution, tesamorelin reduced limb fat more than placebo.
Peptide
Tesamorelin
Outcome
DecreaseLimb fat change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD limb fat
−0.22 kg
tesamorelin versus placebo
Source sentences
Summary
limb fat (MD=-0.22 kg, 95 % CI [-0.35, -0.08]; P = 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorelin versus placebo in adults with HIV.
Summary · context
Five RCTs evaluating Tesamorelin were included in the analysis.
Report a problemFND-4154526103
04HumanSystematic reviewEfficacy outcome
In adults with HIV-associated lipodystrophy, tesamorelin significantly reduced hepatic fat percentage versus placebo.
In plain wordsIn adults with HIV-related fat redistribution, tesamorelin reduced liver fat more than placebo.
Peptide
Tesamorelin
Outcome
DecreaseHepatic fat percentage change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
MD hepatic fat percentage
−4.28%
tesamorelin versus placebo
Source sentences
Summary
hepatic fat percentage (MD=-4.28 %, 95 % CI [-6.31, -2.24]; P < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorelin versus placebo in adults with HIV.
Summary · context
Five RCTs evaluating Tesamorelin were included in the analysis.
Report a problemFND-4154526104
05HumanSystematic reviewEfficacy outcome
In adults with HIV-associated lipodystrophy, tesamorelin significantly reduced waist circumference versus placebo.
In plain wordsIn adults with HIV-related fat redistribution, tesamorelin reduced waist size more than placebo.
Peptide
Tesamorelin
Outcome
DecreaseWaist circumference change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD waist circumference
−1.61 cm
tesamorelin versus placebo
Source sentences
Summary
waist circumference (MD=-1.61 cm, 95 % CI [-2.28, -0.95]; P < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorelin versus placebo in adults with HIV.
Summary · context
Five RCTs evaluating Tesamorelin were included in the analysis.
Report a problemFND-4154526105
06HumanSystematic reviewEfficacy outcome
In adults with HIV-associated lipodystrophy, tesamorelin significantly increased lean body mass versus placebo.
In plain wordsIn adults with HIV-related fat redistribution, tesamorelin increased lean body mass more than placebo.
Peptide
Tesamorelin
Outcome
IncreaseLean body mass change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD lean body mass
1.42 kg
tesamorelin versus placebo
Source sentences
Summary
A significant increase in lean body mass was observed (MD=1.42 kg, 95 % CI [1.13, 1.71]; P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorelin versus placebo in adults with HIV.
Summary · context
Five RCTs evaluating Tesamorelin were included in the analysis.
Report a problemFND-4154526106
07HumanSystematic reviewEfficacy outcome
In adults with HIV-associated lipodystrophy, tesamorelin did not significantly reduce subcutaneous adipose tissue versus placebo.
In plain wordsIn adults with HIV-related fat redistribution, tesamorelin did not clearly reduce fat under the skin compared with placebo.
Peptide
Tesamorelin
Outcome
No significant changeSubcutaneous adipose tissue change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
no significant reductions in subcutaneous adipose tissue or BMI were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorelin versus placebo in adults with HIV.
Summary · context
Five RCTs evaluating Tesamorelin were included in the analysis.
Report a problemFND-4154526107
08HumanSystematic reviewEfficacy outcome
In adults with HIV-associated lipodystrophy, tesamorelin did not significantly reduce BMI versus placebo.
In plain wordsIn adults with HIV-related fat redistribution, tesamorelin did not clearly change BMI compared with placebo.
Peptide
Tesamorelin
Outcome
No significant changeBMI change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
no significant reductions in subcutaneous adipose tissue or BMI
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorelin versus placebo in adults with HIV.
Summary · context
Five RCTs evaluating Tesamorelin were included in the analysis.
Report a problemFND-4154526108
09HumanSystematic reviewEfficacy outcome
In adults with HIV, tesamorelin showed no significant change in CD4 + T-cell counts versus placebo.
In plain wordsIn adults with HIV, tesamorelin did not clearly change CD4 T-cell counts compared with placebo.
Peptide
Tesamorelin
Outcome
No significant changeCD4 + T-cell count change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Tesamorelin showed no significant change in CD4 + T-cell counts.
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorelin versus placebo in adults with HIV.
Summary · context
Five RCTs evaluating Tesamorelin were included in the analysis.
Report a problemFND-4154526109
10HumanSystematic reviewSafety outcome
In adults with HIV-associated lipodystrophy, tesamorelin was associated with arthralgia.
In plain wordsIn adults with HIV-related fat redistribution, tesamorelin was linked to joint pain.
Peptide
Tesamorelin
Outcome
IncreaseArthralgia
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Tesamorelin was associated with adverse events, including arthralgia, myalgia, paresthesia, and injection-site reactions like erythema.
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorelin versus placebo in adults with HIV.
Summary · context
Five RCTs evaluating Tesamorelin were included in the analysis.
Report a problemFND-4154526110
11HumanSystematic reviewSafety outcome
In adults with HIV-associated lipodystrophy, tesamorelin was associated with myalgia.
In plain wordsIn adults with HIV-related fat redistribution, tesamorelin was linked to muscle pain.
Peptide
Tesamorelin
Outcome
IncreaseMyalgia
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Tesamorelin was associated with adverse events, including arthralgia, myalgia, paresthesia, and injection-site reactions like erythema.
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorelin versus placebo in adults with HIV.
Summary · context
Five RCTs evaluating Tesamorelin were included in the analysis.
Report a problemFND-4154526111
12HumanSystematic reviewSafety outcome
In adults with HIV-associated lipodystrophy, tesamorelin was associated with paresthesia.
In plain wordsIn adults with HIV-related fat redistribution, tesamorelin was linked to tingling or numb sensations.
Peptide
Tesamorelin
Outcome
IncreaseParesthesia
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Tesamorelin was associated with adverse events, including arthralgia, myalgia, paresthesia, and injection-site reactions like erythema.
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorelin versus placebo in adults with HIV.
Summary · context
Five RCTs evaluating Tesamorelin were included in the analysis.
Report a problemFND-4154526112
13HumanSystematic reviewSafety outcome
In adults with HIV-associated lipodystrophy, tesamorelin was associated with injection-site reactions such as erythema.
In plain wordsIn adults with HIV-related fat redistribution, tesamorelin was linked to injection-site reactions such as redness.
Peptide
Tesamorelin
Outcome
IncreaseInjection-site reactions including erythema
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Skin and wound
Studied dose
Dose not stated
Source sentences
Summary
Tesamorelin was associated with adverse events, including arthralgia, myalgia, paresthesia, and injection-site reactions like erythema.
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched PubMed, Embase, Scopus, Web of Science, and CENTRAL through July 2025 for randomized controlled trials (RCTs) evaluating Tesamorelin versus placebo in adults with HIV.
Summary · context
Five RCTs evaluating Tesamorelin were included in the analysis.
Report a problemFND-4154526113

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.